The top 3 products of the US business contributed around 25-30 percent to the overall US revenues.

Cipla Q2 PAT seen up 17% YoY to Rs. 442.8 cr: Emkay

Net Sales are expected to increase by 7.4 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 4,308.8 crore, according to Emkay.

Cipla Q1 PAT seen up 4.1% YoY to Rs. 465.1 cr: Prabhudas Lilladher

Net Sales are expected to increase by 10.7 percent Y-o-Y (down 0.3 percent Q-o-Q) to Rs. 4,257.3 crore, according to Prabhudas Lilladher.

Cipla Q4 PAT seen up 93.2% YoY to Rs. 295.8 cr: Kotak

Net Sales are expected to increase by 7.3 percent Y-o-Y (down 1 percent Q-o-Q) to Rs. 3,969.1 crore, according to Kotak.

Cipla Q4 PAT seen up 58.5% YoY to Rs. 283.1 cr: Prabhudas Lilladher

Net Sales are expected to increase by 9.5 percent Y-o-Y (down 2 percent Q-o-Q) to Rs. 3,829.1 crore, according to Prabhudas Lilladher.

Cipla Q3 preview: Brokerages say firm facing global challenges; muted performance likely

EBITDA margin is likely to contract by 325 bps YoY to 17.7% due to high material cost and muted sales growth in domestic business, Reliance Securities said

Cipla Q3 PAT may dip 14% YoY to Rs. 405 cr: Sharekhan

Net Sales are expected to increase by 6.9 percent Y-o-Y (up 4.3 percent Q-o-Q) to Rs. 4,185.8 crore, according to Sharekhan.

Cipla Q3 PAT may dip 27.6% YoY to Rs. 290.1 cr: ICICI Direct

Net Sales are expected to increase by 4.3 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 4,081.6 crore, according to ICICI Direct.

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings

Brokerages such as HSBC, Credit Suisse and Citi have downgraded the stock based on the company’s guidance ahead.

Cipla Q2 PAT may dip 6.7% YoY to Rs. 390 cr: HDFC Securities

Net Sales are expected to increase by 8.8 percent Y-o-Y (up 12.7 percent Q-o-Q) to Rs. 4,440 crore, according to HDFC Securities.

Cipla Q2 PAT seen up 3% YoY to Rs. 450.4 cr: Sharekhan

Net Sales are expected to increase by 7.8 percent Y-o-Y (up 11.7 percent Q-o-Q) to Rs. 4,401.4 crore, according to Sharekhan.

Cipla Q2 PAT may dip 12.7% YoY to Rs. 368.9 cr: ICICI Direct

Net Sales are expected to decrease by 1 percent Y-o-Y (up 2.6 percent Q-o-Q) to Rs. 4,042.4 crore, according to ICICI Direct.

Cipla spikes 4% after it reports 10% rise in net profit to Rs 451 crore; Macquarie maintains outperform rating

Cipla had reported a net profit of Rs 408.8 crore for the corresponding quarter a year ago.

Cipla Q1 PAT may dip 21.3% YoY to Rs. 321.8 cr: Kotak

Net Sales are expected to increase by 9.5 percent Y-o-Y (up 4.4 percent Q-o-Q) to Rs. 3,859.1 crore, according to Kotak.

Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

"For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

Cipla Q4 PAT seen up 57.7% YoY to Rs. 322 cr: Edelweiss

Net Sales are expected to increase by 6.2 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 3,805.3 crore, according to Edelweiss.

Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

US, India will continue to outperform going ahead: Cipla

In an interview with CNBC-TV18, Kedar Upadhye, Group CFO of Cipla spoke about the results and his outlook for the company.

Cipla rallies 7% as global analysts remain positive post Q3 earnings, management commentary

CLSA estimates robust 30 percent earnings CAGR for FY18-20, while retaining Buy rating on the stock with a target price of Rs 750 per share.

Cipla Q3 profit seen up 13%; generic Renvela, Pulmicort, Dacogen may drive US biz

Operating profit is expected to increase 16.7 percent year-on-year to Rs 791 crore and margin may expand 70 basis points to 19.3 percent in Q3.

Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

Cipla Q2 profit seen up 17%; export formulations business may grow around 10%

Margin improvement will be closely watched as it had expanded sharply in Q1 to 18.3 percent from 16.7 percent YoY, added product mix improving and cost control.

Cipla Q2 PAT seen up 13% YoY to Rs. 406 cr: Kotak

Net Sales are expected to increase by 6.7 percent Y-o-Y (up 13.5 percent Q-o-Q) to Rs. 4001 crore, according to Kotak.

Targeting 15% growth for FY18, export will pick up sizeably: Omkar Speciality

In an interview to CNBC-TV18, Pravin Herlekar, CMD of Omkar Speciality Chemicals discussed the company's Q1 performance.